Literature DB >> 12440777

Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis.

B Bolon1, G Campagnuolo, U Feige.   

Abstract

Daily osteoprotegerin (OPG) injection for 7 or more days prevents bone loss for 3 weeks in rats with adjuvant-induced arthritis (AdA). The present experiments defined the duration of bone protection in AdA provided by a single OPG bolus. Male Lewis rats received OPG at the onset or peak of clinical disease, after which bone mineral density (BMD), erosions, and osteoclasts were evaluated. An OPG bolus (4 mg/kg subcutaneously) at onset eliminated osteoclasts, preserved BMD for 7 days, and prevented bone erosions for 4 days. In contrast, an OPG bolus (1, 3, 10, or 30 mg/kg intravenously) given at the peak of disease eradicated osteoclasts in a dose-dependent manner but had no impact on bone integrity due to extensive pre-existing bone loss. These data indicate that one OPG injection will inhibit joint erosions for several days, and confirm that bone-sparing therapy must be initiated early in disease to protect joint integrity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12440777     DOI: 10.1007/s00018-002-8530-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  13 in total

1.  Effect of triptolide on expression of receptor activator of nuclear factor-kappaB ligand in rat adjuvant induced arthritis.

Authors:  Yonghong Hu; Bo Luo; Mingmin Zhang; Shenghao Tu; Keqing Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

2.  HgCl2 challenge in Brown Norway rats lead to dermatitis instead of arthritis.

Authors:  K Schümann; A Lebeau; T Ettle; O Adam
Journal:  Rheumatol Int       Date:  2005-07-16       Impact factor: 2.631

Review 3.  IKK{beta} as a target for treatment of inflammation induced bone loss.

Authors:  M G Ruocco; M Karin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

4.  Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.

Authors:  Y Li; D Li; Y Li; S Wu; S Jiang; T Lin; L Xia; H Shen; J Lu
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

5.  Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.

Authors:  Marc Baud'huin; Laurence Duplomb; Stéphane Téletchéa; Céline Charrier; Mike Maillasson; Marc Fouassier; Dominique Heymann
Journal:  J Biol Chem       Date:  2009-09-16       Impact factor: 5.157

6.  Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement.

Authors:  Matthew D Dunn; Chan Ho Park; Paul J Kostenuik; Sunil Kapila; William V Giannobile
Journal:  Bone       Date:  2007-05-08       Impact factor: 4.398

Review 7.  Promising bone-related therapeutic targets for rheumatoid arthritis.

Authors:  Yongwon Choi; Joseph R Arron; Michael J Townsend
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

8.  The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Authors:  Marina Stolina; Brad Bolon; Scot Middleton; Denise Dwyer; Heather Brown; Diane Duryea; Li Zhu; Alison Rohner; James Pretorius; Paul Kostenuik; Ulrich Feige; Debra Zack
Journal:  J Clin Immunol       Date:  2008-08-26       Impact factor: 8.317

Review 9.  Skeletal and extraskeletal actions of denosumab.

Authors:  Kathrin Sinningen; Elena Tsourdi; Martina Rauner; Tilman D Rachner; Christine Hamann; Lorenz C Hofbauer
Journal:  Endocrine       Date:  2012-05-13       Impact factor: 3.633

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.